Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
Rámón Colomer(Hospital Universitario de La Princesa), Belén Lloveras(Hospital Universitario 12 De Octubre), Agustí Barnadas, Antonio Casado(Hospital Clínico San Carlos), Sagrario Montero, B. Ojeda(Apple (Israel)), Bartomeu Massutí(Universitat de Miguel Hernández d'Elx), H. Cortés-Funes(Centre Hospitalier René-Dubos), Aňa Lluch(Hospital Clínico Universitario de Valencia)
PubMed
June 1, 2000
Cited by 172
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers
|UCL Discovery (University College London)|1997|1k